All questionsSpecific populations: Stelara (ustekinumab), all indications3 questions · 1 sourcePregnancy and breastfeedingIs Stelara safe during pregnancy?“Available data from the Organization of Teratology Information Specialists (OTIS)/MotherToBaby STELARA Pregnancy Registry, published literature and pharmacovigilance in pregnant women have not identified a STELARA- associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes (see Data).” (opens the source at this quote in a new tab)CopyFlag“In animal reproductive and developmental toxicity studies, no adverse developmental effects were observed in offspring after administration of ustekinumab to pregnant monkeys at exposures greater than 100 times the maximum recommended human dose (MRHD).” (opens the source at this quote in a new tab)CopyFlag“Transport of endogenous IgG antibodies across the placenta increases as pregnancy progresses, and peaks during the third trimester. Therefore, STELARA may be present in infants exposed in utero. The potential clinical impact of ustekinumab exposure in infants exposed in utero should be considered.” (opens the source at this quote in a new tab)CopyFlag“The pregnancy registry did not identify a STELARA-associated risk of major birth defects, pattern of major or minor anomalies, increased risk of miscarriage or adverse infant outcomes. Methodological limitations of the registry include small sample size, lack of an internal comparison group, a mix of prospective and retrospective reports, and unmeasured confounders.” (opens the source at this quote in a new tab)CopyFlagCan you breastfeed while taking Stelara?“Limited data from published literature suggests that ustekinumab is present in human breast milk. There are no available data on the effects of ustekinumab on milk production. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to ustekinumab are unknown. No adverse effects on the breastfed infant causally related to ustekinumab have been identified in the published literature or postmarketing experience. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for STELARA and any potential adverse effects on the breastfed child from STELARA or from the underlying maternal condition.” (opens the source at this quote in a new tab)CopyFlagSpecific populationsHas Stelara been studied in adults 65 and older?“Of the 6709 subjects exposed to STELARA, a total of 340 were 65 years of age or older (183 subjects with plaque psoriasis, 65 subjects with psoriatic arthritis, 58 subjects with Crohn’s disease, and 34 subjects with ulcerative colitis), and 40 subjects were 75 years of age or older. Clinical trials of STELARA did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.” (opens the source at this quote in a new tab)CopyFlag“A population pharmacokinetic analysis (N=106/1937 subjects with plaque psoriasis greater than or equal to 65 years old) was performed to evaluate the effect of age on the pharmacokinetics of ustekinumab. There were no apparent changes in pharmacokinetic parameters (clearance and volume of distribution) in subjects older than 65 years old.” (opens the source at this quote in a new tab)CopyFlag